Payment overview · 2025
General Payments
$306.36
16 reported records · 11 companies
Healthcare provider profile · identity verified
Shivani Sharma, MD
Allopathic & Osteopathic Physicians|Family Medicine · HIGHLAND, IL · NPI 1508342189
Verified facts
What the public records show
CMS Open Payments records show Shivani Sharma, MD received $306.36 in general payments during 2025 across 16 reported records.
Collegium Pharmaceutical, Inc. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.62 | 17.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.94 | 14.7% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $36.23 | 11.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.90 | 11.4% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.37 | 8.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.66 | 8.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.19 | 6.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.84 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.26 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.47 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.88 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $306.36 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $52.62 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.94 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 157 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
157 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 932 | 249 |
| Atorvastatin Calcium | Atorvastatin Calcium | 778 | 227 |
| Lisinopril | Lisinopril | 726 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 706 | 174 |
| Gabapentin | Gabapentin | 532 | 119 |
| Omeprazole | Omeprazole | 361 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 336 | 97 |
| Metformin Hcl | Metformin Hcl | 322 | 89 |
| Losartan Potassium | Losartan Potassium | 310 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 86 |
| Furosemide | Furosemide | 304 | 79 |
| Simvastatin | Simvastatin | 300 | 77 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 282 | 94 |
| Alprazolam | Alprazolam | 260 | 40 |
| Sertraline Hcl | Sertraline Hcl | 250 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 235 | 74 |
| Trazodone Hcl | Trazodone Hcl | 232 | 67 |
| Allopurinol | Allopurinol | 220 | 58 |
| Eliquis | Apixaban | 209 | 43 |
| Tramadol Hcl | Tramadol Hcl | 209 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 58 |
| Meloxicam | Meloxicam | 196 | 63 |
| Montelukast Sodium | Montelukast Sodium | 195 | 53 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 193 | 50 |
| Metformin Hcl Er | Metformin Hcl | 187 | 53 |
| Buspirone Hcl | Buspirone Hcl | 186 | 44 |
| Potassium Chloride | Potassium Chloride | 177 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 44 |
| Mounjaro | Tirzepatide | 157 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 145 | 40 |
| Jardiance | Empagliflozin | 137 | 40 |
| Prednisone | Prednisone | 137 | 102 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 55 |
| Farxiga | Dapagliflozin Propanediol | 134 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 116 | 34 |
| Famotidine | Famotidine | 115 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 30 |
| Ozempic | Semaglutide | 111 | 29 |
| Pregabalin | Pregabalin | 108 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 103 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 27 |
| Methylprednisolone | Methylprednisolone | 99 | 85 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 27 |
| Donepezil Hcl | Donepezil Hcl | 95 | 26 |
| Glipizide | Glipizide | 94 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 22 |
| Celecoxib | Celecoxib | 92 | 32 |
| Finasteride | Finasteride | 92 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 22 |
| Carvedilol | Carvedilol | 86 | 25 |
| Cephalexin | Cephalexin | 86 | 57 |
| Warfarin Sodium | Warfarin Sodium | 85 | 17 |
| Trulicity | Dulaglutide | 83 | 22 |
| Lovastatin | Lovastatin | 81 | 22 |
| Glimepiride | Glimepiride | 77 | 23 |
| Lorazepam | Lorazepam | 75 | 20 |
| Glipizide Er | Glipizide | 68 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 15 |
| Valsartan | Valsartan | 62 | 17 |
| Chlorthalidone | Chlorthalidone | 59 | 20 |
| Ezetimibe | Ezetimibe | 59 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 19 |
| Lamotrigine | Lamotrigine | 56 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 15 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 15 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Meclizine Hcl | Meclizine Hcl | 46 | 19 |
| Atenolol | Atenolol | 45 | 12 |
| Azithromycin | Azithromycin | 45 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Estradiol | Estradiol | 44 | 15 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | 14 |
| Colestipol Hcl | Colestipol Hcl | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Folic Acid | Folic Acid | 39 | 13 |
| Sucralfate | Sucralfate | 39 | 18 |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Ondansetron Odt | Ondansetron | 35 | 17 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 25 |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Ketoconazole | Ketoconazole | 32 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 29 | 13 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Benzonatate | Benzonatate | 18 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 11 |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $306.36 · 16 records | Collegium Pharmaceutical, Inc. | Azstarys, CREON, Cologuard Collection Kit, FREESTYLE LIBRE 3, GEMTESA, INGREZZA, JARDIANCE, Jornay PM, LINZESS, MOUNJARO, Ozempic, Rybelsus, TRINTELLIX, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error